Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-11-21
2006-11-21
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S284000
Reexamination Certificate
active
07138389
ABSTRACT:
This invention provides methods of treating a mammalian subject in need of androgen therapy by orally administering to the subject testosterone, a testosterone ester, or a testosterone precursor in an oil vehicle and by administering to the subject a modulator such as finasteride or dutasteride which increases testosterone bioavailability in the subject.
REFERENCES:
patent: 4377584 (1983-03-01), Rasmusson et al.
patent: 5998427 (1999-12-01), Batchelor et al.
patent: 6117429 (2000-09-01), Bucci
patent: 6696484 (2004-02-01), Liao et al.
patent: 2003/0203043 (2003-10-01), Yegorova
patent: 2004/0110733 (2004-06-01), Borlak et al.
patent: WO 99/65228 (1999-12-01), None
Aakvaag, A. et al. “Plasma Testosterone Values In Different Forms Of Testosterone Treatment.”Acta Endocrinologica(1969), 60:537-542.
Amory, J.K. et al. “Oral Testosterone-Triglyceride Conjugate in Rabbits: Single-Dose Pharmacokinetics and Comparison With Oral Testosterone Undecanoate.”J Androl.(Sep./Oct. 2003), 24(5):716-720.
Amory, J.K. et al. “Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone.”J Clin Endocrinol&Metab(2004), 89(2):503-510.
Bagchus, Wilma M. et al. “Important Effect Of Food On The Bioavailability Of Oral Testosterone Undecanoate.”Pharmacotherapy(Nov. 3, 2003), 23(3):319-325.
Chang, William Y. et al. “Experimentally-Induced Prostatic Hyperplasia in Young Beagles: A Model to Evaluate the Chemotherapeutic Effects of Gossypol.”Res Commun Mol Pathol Pharmacol(Jun. 1996), 92(3):341-360.
Daggett, P.R. et al. “Oral Testosterone, a Reappraisal.”Hormone Res.(1978), 9:121-129.
Foss, George L. “Clinical Administration of Androgens, A Comparison of Various Methods.”The Lancet(Mar. 4, 1939), pp. 502-504.
Franchi, F. et al. “Long-Term Study of Oral Testosterone Undecanoate in Hypogonadal Males.”International Journal of Andrology(1978), 1:270-278.
Frey, H. et al. “Bioavailability of Oral Testosterone in Males.”European Journal of Clinical Pharmacology(1979), 16:345-349.
Gormley, Glenn J. et al. “Effects of Finasteride (MK-906), a 5α-Reductase Inhibitor, on Circulating Androgens in Male Volunteers.”Journal of Clinical Endocrinology and Metabolism(Apr. 1990), 70(4):1136-1141.
Herzog, Andrew G. et al. “Testosterone versus testosterone and testolactone in treating reproductive and sexual dysfunction in men with epilepsy and hypogonadism.”Neurology(Mar. 1998), 50(3):782-784.
Houwing, Natalie S. et al. “Pharmacokinetic Study in Women of Three Different Doses of a New Formulation of Oral Testosterone Undecanoate, Andriol Testocaps.”Pharmacotherapy(Nov. 10, 2003), 23(10):1257-1265.
Johnsen, Svend G. et al. “Therapeutic Effectiveness of Oral Testosterone.”The Lancet(Dec. 21, 1974), pp. 1473-1475.
Kinniburgh, D. et al. “Suppression of Spermatogenesis With Desogestrel and Testosterone Pellets is Not Enhanced by Addition of Finasteride.”J Androl(Jan.-Feb. 2001), 22(1):88-95.
McLachlan, Robert I. et al. “Efficacy and acceptability of testosterone implants, alone or in combination with a 5α-reductase inhibitor, for male hormonal contraception,”Contraception(Aug. 2000), 62(2):73-78.
Nieschlag, E. et al. “Plasma Androgen Levels in Men After Oral Administration of Testosterone or Testosterone Undecanoate.”Acta Endocrinologica(1975), 79:366-374.
Rittmaster, Roger S. “5α-Reductase Inhibitors.”J Androl(Nov./Dec. 1997), 18(6):582-587.
Schürmeyer, E.J. et al. “Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men.”Acta Endocrinologica(1983), 102:456-462.
Skakkebaek, N.E. et al. “Androgen Replacement With Oral Testosterone Undecanoate In Hypogonadal Men: A Double Blind Controlled Study.”Clinical Endocrinology(1981), 14:49-61.
Täuber, U., et al. “Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone.”European J of Drug Metab&Pharmacokinetics(1986), 11(2):145-149.
Wright, A.S. et al. “Androgen-Induced Regrowth in the Castrated Rat Ventral Prostrate: Role of 5α-Reductase.”Endocrinology(1999), 140(10):4509-4515.
Umekita, Yoshihisa et al. “Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.”Proc. Natl. Acad. Sci.(Oct. 1996), 93:11802-11807.
Amory John K.
Bremner William J.
Badio Barbara P.
Townsend and Townsend / and Crew LLP
University of Washington
LandOfFree
Oral androgen therapy using modulators of testosterone... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral androgen therapy using modulators of testosterone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral androgen therapy using modulators of testosterone... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3682700